NCT07606872Enrolling by invitation
Validation of the Snouda Metabolic Score for Phenotyping and Guiding Reversal in Type 2 Diabetes
A Prospective Interventional Clinical Validation Study of the Snouda Metabolic Score (SMS) as a Phenotyping and Protocol-Targeting Instrument in Adults With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
This study tests a new tool called the Snouda Metabolic Score (SMS) that helps doctors identify the specific metabolic problems driving Type 2 Diabetes in each individual patient. Instead of treating all diabetic patients the same way, the SMS classifies patients into one of several metabolic phenotypes - patterns of dysfunction across five body systems: insulin resistance, chronic inflammation, hormonal disruption, gut microbiome imbalance, and mitochondrial dysfunction. Once classified, each participant follows a personalized 24-week lifestyle and nutritional protocol targeting their specific phenotype. The protocol includes dietary changes, structured exercise, targeted nutritional supplements, and optional intermittent fasting. Participants track their blood glucose daily and complete biomarker blood tests at the start and end of the study. The main goal is to determine whether the SMS tool accurately identifies metabolic phenotypes and whether phenotype-matched protocols produce better outcomes than standard approaches. The study measures changes in HbA1c, fasting insulin, C-peptide, inflammation markers, and whether participants achieve Type 2 Diabetes remission - defined as HbA1c below 6.5% without glucose-lowering medication. The study is conducted entirely online through the diabetesreversal.io platform. There are no clinic visits required. Participants must be adults aged 18 or older with a confirmed Type 2 Diabetes diagnosis and must not be pregnant or breastfeeding.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 19 May 2026
- Start date
- Aug 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Salah Snouda
- Diseases
- Type 2 diabetes
- NCT number
- NCT07606872
What you commit to
- Study type: Interventional
- Planned participants: 150
- From Aug 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently using insulin therapy
- Currently using GLP-1 receptor agonists (e.g., semaglutide, liraglutide)
- Active malignancy or receiving chemotherapy or radiation therapy
Other illness
- Type 1 Diabetes Mellitus or Latent Autoimmune Diabetes in Adults (LADA)
- History of severe hypoglycemia requiring third-party assistance in the past 12 months
- Severe hepatic impairment
- Active eating disorder
- Any condition that in the opinion of the investigator would make participation unsafe or interfere with study completion
Lab values
- HbA1c greater than 11.0% at baseline
- Severe renal impairment (eGFR less than 30 mL/min/1.73m²)
Other
- Currently pregnant or breastfeeding
Who the study is looking for
- Confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) by a licensed healthcare provider
- Age 18 years or older
- HbA1c between 6.5% and 11.0% at baseline
- Currently managed with lifestyle measures alone, or with oral glucose-lowering medications (metformin, SGLT2 inhibitors, DPP-4 inhibitors, or sulfonylureas)
- Ability to access and use the diabetesreversal.io digital platform
- Willingness to perform daily self-monitoring of blood glucose
- Willingness to complete laboratory blood tests (Genesis Biomarker Panel) at baseline and Week 24 at own expense
- Able to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Snouda Health Coaching Ltd Coordinator of this site? Confirm its status | Manchester | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.